Wilson JC, et al. - In rheumatoid arthritis (RA) and non-RA patients, authors assessed the incidence of glucocorticoid (GC)-related serious adverse events (SAEs) using the UK Clinical Practice Research Datalink (CPRD) and quantified their risk in RA patients. In a cohort analysis, the incidence rates and incidence rate ratios (IRRs) were evaluated for GC-related AEs (ie, diabetes, osteoporosis, fractures, glaucoma, hypertension, GI perforation or bleeding, ‘thrombotic stroke or MI’, death), stratified by GC use. An increased incidence of GC-related AEs was seen in RA patients. They noted an association of increasing cumulative and average daily GC doses with increasing risk of developing an AE.